TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Positive interim results announced for TRPH-222 in patients with NHL

By Alia Mohamed

Share:

May 21, 2020


On May 18, 2020, positive interim results were announced from the multi-center, open-label, phase I study of TRPH-222 (NCT03682796). This trial investigated the efficacy and safety of the next-generation antibody-drug conjugate, TRPH-222, in heavily pre-treated patients with relapsed and/or refractory B-cell lymphoma (non-Hodgkin lymphoma; NHL).  The primary aim was to determine the maximum tolerated dose of TRPH-222; the secondary aims were to assess the safety, anti-tumor activity, and the pharmacokinetics. 1, 2

Data from the trial demonstrated early signs of a potential therapeutic benefit in the dose-escalation stage. Of the 19 heavily pretreated patients with NHL, five patients achieved a complete response at doses of 0.6 – 4.2 mg/kg every 3 weeks. Tumor reductions were seen in patients with both indolent and aggressive disease. Patients with follicular, diffuse large cell, and mantle cell lymphoma maintained a durable response. TRPH-222 was well-tolerated with a benign safety profile. The trial is currently ongoing with dose level of 10 mg/kg every 3 weeks. 1, 2

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content